Status:
COMPLETED
Use of Endogenous Melatonin and 6-hydroxymelatonin as Biomarkers for CYP1A2
Lead Sponsor:
Youssef Daali
Conditions:
Healthy
Eligibility:
All Genders
18+ years
Brief Summary
An observational study comprising 4 sessions will be conducted in 12 healthy volunteers. During each study session (sessions 1 to 4), a 12-hour urine collection during the night (21h-9h) will be carri...
Eligibility Criteria
Inclusion
- Healthy men and women
- Understanding of French language and ability to give a written informed consent
Exclusion
- Inability to refrain from alcohol or methylxanthine-containing beverages and foods for 24 hours
- Sensitivity to coffee or CocaCola®
- Irregular (i.e. non-daily or inconstant dosages) intake of medication or food of a CYP1A2 modulator (including tobacco)
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04420611
Start Date
October 1 2020
End Date
December 30 2020
Last Update
May 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Geneva University Hospitals
Geneva, Switzerland